GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » 5-Year Yield-on-Cost %

CNSP (CNS Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 23, 2025)


View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals 5-Year Yield-on-Cost %?

CNS Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for CNS Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



CNSP's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.65
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of CNS Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, CNS Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNS Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where CNS Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


;
;

CNS Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of CNS Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

CNS Pharmaceuticals  (NAS:CNSP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


CNS Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of CNS Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


CNS Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Executives
Christopher Downs officer: Chief Financial Officer 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco director, officer: Chief Executive Officer PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes director 13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027